Clinical Trial Update: A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Vosoritide versus placebo in children with hypochondroplasia aged 0 to < 36 months is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypochondroplasia

Drugs mentioned

• Vosoritide (vosoritide)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hypochondroplasia | Phase 2 | Status: RECRUITING